Aalst, Belgium
Aalst, Belgium

Time filter

Source Type

Ferguson G.T.,Pulmonary Research Institute of Southeast Michigan | Feldman G.J.,S Carolina Pharmaceutical Research | Hofbauer P.,Pneumologie | Hamilto A.,Boehringer Ingelheim | And 3 more authors.
International Journal of COPD | Year: 2014

Background: Olodaterol is a long-acting β2-agonist with a 24-hour bronchodilator profile. Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving usual-care background therapy. Methods: Patients received olodaterol 5 μg or 10 μg or placebo once daily for 48 weeks. Coprimary end points were forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 3 hours (AUC0-3) response (change from baseline), and trough FEV1 response at 12 weeks. Secondary end points included additional lung function assessments, use of rescue medications, FEV1 AUC response from 0 to 12 hours, and Patient Global Rating over 48 weeks. Results: Overall, 624 and 642 patients were evaluated in studies 1222.11 and 1222.12, respectively. In both studies, olodaterol 5 μg and 10 μg significantly improved the FEV1 AUC0-3 response (P<0.0001) and trough FEV1 (study 1222.11, P<0.0001; study 1222.12, P<0.05, post hoc) at week 12, with an incidence of adverse events comparable with that of placebo. Secondary end points supported the efficacy of olodaterol. Conclusion: These studies demonstrate the long-term efficacy and safety of once-daily olodaterol 5 μg and 10 μg in patients with moderate to very severe COPD continuing with usual-care maintenance therapy. © 2014 Ferguson et al.

Preliminary results of an important collaborative initiative with IUCPQ presented at 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria WINNIPEG, MB--(Marketwired - December 07, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") presented the preliminary results of an important collaborative initiative between the Company and the Institut Universitaire de Cardiologie et de Pneumologie De Quebec (IUCPQ) exploring the possibility of identifying a biological marker to distinguish between two deadly forms of lung cancer, multiple synchronous lung adenocarcinoma (AC) and metastatic lung AC, which is a significant unmet clinical need in the management of patients with multiple lung lesions. In every blinded patient sample the Company analyzed, 3DS technology was able to distinguish between the two respective types of deadly lung cancer. The poster is being presented at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) taking place in Vienna, Austria from December 4 to 7, 2016. 3DS technology was used to differentiate blindly between 19 lung cancer patients, 10 with synchronous lung AC and 9 with metastatic AC. Patient tissue samples were provided by the Biobank at IUCPQ and the experimental study design was the result of a fruitful collaboration between Dr. Philippe Joubert, Thoracic Pathologist and Scientist at IUCPQ, Dr. Sabine Mai, co-founder of 3DS and Dr. Oumar Samassekou, VP Clinical Programs at 3DS. The acquisition of 3D telomere images and analysis was performed in the Company's reference lab using 3DS' proprietary software platform, TeloView™, while the experiments, data analysis and interpretation was performed in a multi-centre collaboration between Dr. Sabine Mai, Dr Philippe Joubert and Nathalie Bastien, a postdoctoral fellow at IUCPQ. Principal Investigator, Dr. Philippe Joubert, and Company Director and Chair of 3DS' Clinical and Scientific Advisory Board, Dr. Sabine Mai stated: This important research would not be possible without the support of IUCPQ. These preliminary results suggest that 3DS has a promising molecular imaging technology that has the potential to improve the management of AC patients who present with multiple lung lesions. Currently, there is no molecular tool to aid clinicians in distinguishing between patients with synchronous lung AC and patients with metastatic lung AC. While only patients with synchronous lung cancer are likely to benefit from surgical resection, it is important for the treating physician to accurately identify these two groups of patients in order to optimize their management. 3DS' platform technology has the potential to help clincians personalize treatments for a significant portion of lung cancer patients -- and potentially improve outcomes in one of the most deadly forms of lung cancer. Additional studies are being planned between IUCPQ and 3DS to further validate these results and move 3DS' novel biomarker closer to commercialization. About the IUCPQ Since its creation in 1918, the Institut Universitaire De Cardiologie et de Pneumologie de Quebec has stood on equal footing with leading North American establishments for ultra-specialized care. Specializing in the health of persons with cardiopulmonary diseases, the Institute is renowned and recognized internationally as a leader. What distinguishes the Institute is its expertise and innovative practices, its focus on research and teaching, and its technological advances. The Institute is where specialized expertise and the sharing of knowledge come together in an ongoing quest for excellence. The close and continuing synergy between clinical activities, research, teaching and the evaluation of health technologies and interventions ensures a care approach guided by best practices and forms the cornerstone of the Institute's mission. About the World Lung Cancer Conference The IASLC World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated to lung cancer and other thoracic malignancies. More than 7,000 delegates come from more than 100 countries to discuss the latest developments in thoracic malignancy research. Attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients. About 3DS 3DS (TSX VENTURE: DXD) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis chromosomal signatures. The technology is well developed and supported by 16 clinical studies on over 1,500 patients on 13 different cancers and Alzheimer's disease. Depending on the desired application, the technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company's new website at http://www.3dsignatures.com. Forward-Looking Information This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. In particular, the Company's statements that it expects to benefit greatly from its association with the individuals named in this news release is forward-looking information. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company's existing products or the Company's ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the Company's ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Fischer A.,University of Colorado at Denver | Antoniou K.M.,University of Crete | Brown K.K.,National Jewish Health | Cadranel J.,Pneumologie | And 15 more authors.
European Respiratory Journal | Year: 2015

Many patients with an idiopathic interstitial pneumonia (IIP) have clinical features that suggest an underlying autoimmune process but do not meet established criteria for a connective tissue disease (CTD). Researchers have proposed differing criteria and terms to describe these patients, and lack of consensus over nomenclature and classification limits the ability to conduct prospective studies of a uniform cohort. The "European Respiratory Society/American Thoracic Society Task Force on Undifferentiated Forms of Connective Tissue Disease-associated Interstitial Lung Disease" was formed to create consensus regarding the nomenclature and classification criteria for patients with IIP and features of autoimmunity. The task force proposes the term "interstitial pneumonia with autoimmune features" (IPAF) and offers classification criteria organised around the presence of a combination of features from three domains: a clinical domain consisting of specific extra-thoracic features, a serologic domain consisting of specific autoantibodies, and a morphologic domain consisting of specific chest imaging, histopathologic or pulmonary physiologic features. A designation of IPAF should be used to identify individuals with IIP and features suggestive of, but not definitive for, a CTD. With IPAF, a sound platform has been provided from which to launch the requisite future research investigations of a more uniform cohort. Copyright © ERS 2015.

Background: Acute dyspnea is a common cause for emergency calls. In addition to cardiac causes, it may be related to pulmonary diseases. Results: In case of acute dyspnea, bronchial asthma may be primarily considered. However, there are other reasons for severe dyspnea, e.g., paradoxical adduction of the vocal cords (vocal cord dysfunction, VCD). Conclusion: Knowledge of VCD will enable the emergency physician to correctly assess and prevent harmful escalation of the therapeutic regimen. © 2015, Springer-Verlag Berlin Heidelberg.

Monitoring the partial pressure of carbone dioxide is the best means of assessing alveolar ventilation. Recent development in transcutaneous technology has been the introduction of electrodes combining the monitoring of the hemoglobin O2 saturation (SpO2) and of the transcutaneous PCO2 (PtCO2). Response time with currents systems is fast and reliable with recent improvements in PtCO2 drift during prolonged monitoring. Overnight monitoring of PCO2 has become a reliable tool for assessing diagnosis and treatment of alveolar hypoventilation during sleep in patients receiving non-invasive ventilation. Nowadays, the use of this tool is recommended in the recent guidelines of the HAS (Haute Autorité de Santé). © 2013 Elsevier Masson SAS.

Lung cancer is even today the leading cause of cancer mortality worldwide. The majority of patients are still diagnosed with advanced cancer so that curative therapy is feasible only in a minority of patients. The prognosis is up to now poor and palliative therapy unfortunately common. The bronchoscopist is confronted with an increasing number of patients suffering from centrally located cancer with life-threatening symptoms and immediate action is required. In recent years the techniques have been improved. For tumor destruction mechanical removal and different coagulation methods are available. The laser is losing popularity. Electrocoagulation and argon plasma beamer lead to comparable results. Recently cryorecanalization as a form of cryotherapy has become widely used. After removal of the intraluminal component and/or dilatation a stent can be used for securing airway patency. The repertoire also includes brachytherapy, photodynamic therapy and different methods to achieve hemostasis. An overview of the different methods of bronchoscopic tumor palliation and the differential therapy is given. © 2012 Springer-Verlag.

Frasnelli A.,Pneumologie | Frasnelli M.,Notfall
Praxis | Year: 2016

The causes of hemoptysis are various, often the patient's history and physical examination can narrow potential differential diagnosis, and even pseudohemoptysis with a source of bleeding located outside the lungs is possible. A chest radiograph is needed and can identify the cause in up to one third of the cases. © 2016 Hogrefe.

Bauer C.M.,Pneumologie | Schmahl A.,Radiologie | Kreuter M.,Pneumologie
Klinische Monatsblatter fur Augenheilkunde | Year: 2016

Diagnosis of tuberculosis (TB) is difficult, since symptoms are often very unspecific or lacking. However active, prompt and accurate diagnosis is the key element in the public health response to tuberculosis and the cornerstone of tuberculosis control. Different diagnostic methods for an assured diagnosis of TB are necessary. Chest radiography is a useful keystone to identify tuberculosis, but diagnosis of tuberculosis cannot be established by radiography alone. CT scanning is used in patients without pathological chest radiography but clinically suspected active TB and to differentiate TB from other diseases. Radiological appearance is primarily determined by the immune status of patients and caverns and disseminated disease foci are often observed. Laboratory diagnostic methods include microscopic identification of acid-fast mycobacteria from any body fluid (especially sputum), as well as isolation and characterisation of mycobacteria in culture. It is then possible to type the pathogens by the shape of their colony, their growth behavior and their biochemical characteristics. These methods are regarded as the gold standard in diagnosis of active TB. In patients who are highly suspected of having TB, but whose sputum specimens tested negative for mycobacteria, a nucleic acid amplification test is additionally performed. Moreover, sensitivity testing with first and second line antitubercular drugs is applied as standard. Laboratory diagnostic testing of cellular immunity against pathogenic mycobacteria employs the tuberculin skin test (TST, Mantoux tuberculin test) or the more specific interferon γ test to determine γ interferon released by T lymphocytes stimulated in vitro. The new ELISA and ELISPOT procedures exhibit higher test specificity and less cross reactivity to NTM (non-tuberculosis mycobacteria), are independent of BCG-vaccination status and correlate better with the degree of exposure than does the TST. © Georg Thieme Verlag KG Stuttgart New York.

Cadranel J.,Pneumologie
Revue des Maladies Respiratoires Actualites | Year: 2015

The lung is often the target of collagen vascular diseases (CVD), usually with interstitial pneumonia. The type of interstitial lung disease may be a clue to the diagnosis of CVD, and is sometimes very specific (UIP and rheumatoid arthritis, COP and dermatoymyositis, LIP and Sjogren's syndrome). The development of interstitial lung disease affects the prognosis of CVD (Pulmonary hypertension and systemic sclerosis, UIP and Rheumatoid arthritis). Interstitial lung disease associated with CVD usually has a better prognosis than idiopathic interstitial lung disease. Currently, there is no effective specific treatment for interstitial pneumonia associated with CVD except cyclophosphamide in systemic sclerosis. © 2015 Elsevier Inc..

Valeyre D.,University of Paris 13 | Dion G.,Pneumologie
Bulletin de l'Academie Nationale de Medecine | Year: 2010

Idiopathic pulmonary fibrosis (IPF) is a severe disease with a median survival time of only 24-36 months. It is characterized by inexorably progressive respiratory failure and by acute exacerbations that are often rapidly fatal. The standard treatment based on steroids and immunosuppressive drugs is no longer recommended. Lung transplantation is the only treatment with an impact on survival, but it concerns only a minority of patients and must be performed early in the disease process. Patients not eligible for transplantation should be given the opportunity to participate in clinical trials of promising new therapies. Many trials have recently been completed or are currently underway, but few results have been published. In the meantime, supportive treatment (oxygen therapy and rehabilitation), vaccination, and treatment of comorbidities (gastroesophageal reflux, sleep apnea) are recommended.

Loading Pneumologie collaborators
Loading Pneumologie collaborators